Reasoning that since (a) ER is a transcriptional driver in breast cancer cells, (b) CDK7 activity is required for transcription and (c) CDK7 phosphorylates ER at Ser118, we determined if co-treatment with THZ1 and anti-estrogens would provide additional growth inhibition. Here, CDK7 is linked to breast cancer.